Scott M. Coiante
2022
In 2022, Scott M. Coiante earned a total compensation of $1M as Former Chief Financial Officer at Aprea Therapeutics, a 41% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $160,000 |
|---|---|
| Option Awards | $325,968 |
| Salary | $400,000 |
| Stock Awards | $144,350 |
| Total | $1,030,318 |
Coiante received $400K in salary, accounting for 39% of the total pay in 2022.
Coiante also received $160K in non-equity incentive plan, $326K in option awards and $144.4K in stock awards.
Rankings
In 2022, Scott M. Coiante's compensation ranked 2,958th out of 5,756 executives tracked by ExecPay. In other words, Coiante earned more than 48.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,958 out of 5,756 | 49th |
Division Manufacturing | 1,654 out of 3,133 | 47th |
Major group Chemicals And Allied Products | 773 out of 1,419 | 46th |
Industry group Drugs | 722 out of 1,320 | 45th |
Industry Pharmaceutical Preparations | 524 out of 966 | 46th |
Source: SEC filing on July 11, 2023.
Coiante's colleagues
We found four more compensation records of executives who worked with Scott M. Coiante at Aprea Therapeutics in 2022.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020